Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in Patients With Myelodysplastic Syndrome (MDS)
NCT00217594Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2005
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in myelodysplastic syndrome (MDS), sponsored by National Heart, Lung, and Blood Institute. Started Jul 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00217594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00217594.